Business Wire

Firebolt Appoints Carlos Román as EMEA Vice President to Accelerate Regional Expansion

19.3.2025 09:00:00 EET | Business Wire | Press release

Share

Firebolt, the data infrastructure for AI applications, announced the appointment of Carlos Román as Vice President for Europe, the Middle East and Africa (EMEA). In this role, Mr. Román will oversee Firebolt's go-to-market strategies and customer-facing operations across the EMEA region, further solidifying the company's commitment to global growth and innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319698262/en/

Carlos Román, EMEA VP, Firebolt

Mr. Román brings over 25 years of experience leading sales and demand generation within enterprise and digital-native organizations. His extensive background includes key leadership roles at Oracle and Confluent, where he drove exceptional revenue growth and market expansion.

At Confluent, Mr. Román served as Vice President for Digital Native and Emerging Markets in EMEA, leading go-to-market strategy with AWS, Google and Microsoft. Under his leadership, the cloud consumption business experienced unprecedented growth. Previously, Mr. Román held leadership positions at Oracle across Europe, Asia Pacific and the Americas.

Mr. Román’s appointment aligns with Firebolt’s ambitious global expansion strategy, following the recent addition of Hemanth Vedagarbha as President, who oversees global go-to-market initiatives and customer-facing operations.

“Carlos is exactly the kind of leader we need to accelerate our growth in EMEA,” said Mr. Vedagarbha, President at Firebolt. “His proven ability to scale businesses, drive aggressive market expansion and build high-performing teams is second to none. The EMEA region is a critical market for us, and with Carlos at the helm, I have no doubt that Firebolt will quickly become the leading solution for the fastest and most efficient AI-driven applications.”

“Businesses today need a data platform that not only stores information but drives decision making with real-time insights,” said Mr. Román. “Firebolt is designed to address the challenges of real-time data analytics for AI applications, enabling organizations to process vast amounts of data at scale while optimizing costs. That’s a game-changer for organizations looking to scale AI-driven applications, enhance customer experiences and unlock new revenue streams. I’m excited to join the Firebolt family to help businesses across EMEA leverage Firebolt to drive tangible business outcomes.”

Firebolt is expanding its footprint in key verticals such as financial services, e-commerce, gaming, delivery and technology, where real-time analytics and lightning-fast performance are critical for data intensive solutions. Firebolt’s strong presence in key markets including the United Kingdom, Germany and Israel will be expanded to cover fast growing EMEA markets including France, Nordics, Central & Eastern Europe, Middle East and Africa.

About Firebolt

Firebolt is the data infrastructure platform designed to handle the speed, scale, and flexibility of AI applications. By delivering ultra-low latency, high concurrency, multi-dimensional elasticity, and flexibility, Firebolt empowers organizations to build data-intensive AI applications that perform at scale. Built across five years of relentless development, it reflects continuous feedback from users and real-world use cases. Data engineers can now deliver customer-facing analytics and data-intensive applications more cost-effectively and with greater simplicity. Firebolt's innovative approach to data infrastructure is setting new benchmarks in performance and cost efficiency.

For more information, visit www.firebolt.io and follow on LinkedIn.

Try Firebolt Today

Experience the power of Firebolt with our free trial. Sign up now and see firsthand how Firebolt can transform your data strategy.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319698262/en/

Contacts

Media Contact
Sara Delacruz
prforfirebolt@bospar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye